MacArthur, D. G. et al. A systematic survey of loss-of-function variants in human protein-coding genes. Science 335, 823–828 (2012).
Schneeberger, K. Using next-generation sequencing to isolate mutant genes from forward genetic screens. Nat. Rev. Genet. 15, 662–676 (2014).
Zambrowicz, B. P. & Sands, A. T. Knockouts model the 100 best-selling drugs—will they model the next 100? Nat. Rev. Drug Discov. 2, 38–51 (2003).
Lek, M. et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536, 285–291 (2016).
Chong, J. X. et al. The genetic basis of mendelian phenotypes: discoveries, challenges, and opportunities. Am. J. Hum. Genet. 97, 199–215 (2015).
Cohen, J. C., Boerwinkle, E., Mosley, T. H., Jr & Hobbs, H. H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354, 1264–1272 (2006).
Samocha, K. E. et al. A framework for the interpretation of de novo mutation in human disease. Nat. Genet. 46, 944–950 (2014).
Petrovski, S., Wang, Q., Heinzen, E. L., Allen, A. S. & Goldstein, D. B. Genic intolerance to functional variation and the interpretation of personal genomes. PLoS Genet. 9, e1003709 (2013).
Cassa, C. A. et al. Estimating the selective effects of heterozygous protein-truncating variants from human exome data. Nat. Genet. 49, 806–810 (2017).
Petrovski, S. et al. The intolerance of regulatory sequence to genetic variation predicts gene dosage sensitivity. PLoS Genet. 11, e1005492 (2015).
Collins, R. L. et al. A structural variation reference for medical and population genetics. Nature https://doi.org/10.1038/s41586-020-2287-8 (2020).
Minikel, E. V. et al. Evaluating drug targets through human loss-of-function genetic variation. Nature https://doi.org/10.1038/s41586-020-2267-z (2020).
Whiffin, N. et al. The effect of LRRK2 loss-of-function variants in humans. Nature Med. https://doi.org/10.1038/s41591-020-0893-5 (2020).
GTEx Consortium. Genetic effects on gene expression across human tissues. Nature 550, 204–213 (2017).
Cummings, B. B. et al. Transcript expression-aware annotation improves rare variant interpretation. Nature https://doi.org/10.1038/s41586-020-2329-2 (2020).
Wang, Q. et al. Landscape of multi-nucleotide variants in 125,748 human exomes and 15,708 genomes. Nat. Commun. https://doi.org/10.1038/s41467-019-12438-5 (2020).
Whiffin, N. et al. Characterising the loss-of-function impact of 5′ untranslated region variants in whole genome sequence data from 15,708 individuals. Nat. Commun. https://doi.org/10.1038/s41467-019-10717-9 (2019).
Van der Auwera, G. A. et al. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr. Protoc. Bioinformatics 43, 11.10.1–11.19.33 (2013).
Hail Team. Hail 0.2.19; https://github.com/hail-is/hail/releases/tag/0.2.19 (released 2 August 2019).
Jónsson, H. et al. Parental influence on human germline de novo mutations in 1,548 trios from Iceland. Nature 549, 519–522 (2017).
Motenko, H., Neuhauser, S. B., O’Keefe, M. & Richardson, J. E. MouseMine: a new data warehouse for MGI. Mamm. Genome 26, 325–330 (2015).
Eppig, J. T., Blake, J. A., Bult, C. J., Kadin, J. A. & Richardson, J. E. The Mouse Genome Database (MGD): facilitating mouse as a model for human biology and disease. Nucleic Acids Res. 43, D726–D736 (2015).
Hart, T. et al. Evaluation and design of genome-wide CRISPR/SpCas9 knockout screens. G3 (Bethesda) 7, 2719–2727 (2017).
Feiglin, A., Allen, B. K., Kohane, I. S. & Kong, S. W. Comprehensive analysis of tissue-wide gene expression and phenotype data reveals tissues affected in rare genetic disorders. Cell Syst. 5, 140–148.e2 (2017).
Gravel, S. When is selection effective? Genetics 203, 451–462 (2016).
Henn, B. M., Botigué, L. R., Bustamante, C. D., Clark, A. G. & Gravel, S. Estimating the mutation load in human genomes. Nat. Rev. Genet. 16, 333–343 (2015).
Bamshad, M. J., Nickerson, D. A. & Chong, J. X. mendelian gene discovery: fast and furious with no end in sight. Am. J. Hum. Genet. 105, 448–455 (2019).
Walters, J. T. R. et al. The contribution of rare variants to risk of schizophrenia in individuals with and without intellectual disability. Nat. Genet. 511, 421 (2017).
Ganna, A. et al. Quantifying the impact of rare and uTheltra-rare coding variation across the phenotypic spectrum. Am. J. Hum. Genet. 102, 1204–1211 (2018).
Ganna, A. et al. Ultra-rare disruptive and damaging mutations influence educational attainment in the general population. Nat. Neurosci. 19, 1563–1565 (2016).
Genovese, G. et al. Increased burden of ultra-rare protein-altering variants among 4,877 individuals with schizophrenia. Nat. Neurosci. 19, 1433–1441 (2016).
Eilbeck, K., Quinlan, A. & Yandell, M. Settling the score: variant prioritization and Mendelian disease. Nat. Rev. Genet. 18, 599–612 (2017).
DeBoever, C. et al. Medical relevance of protein-truncating variants across 337,205 individuals in the UK Biobank study. Nat. Commun. 9, 1612 (2018).
Emdin, C. A. et al. Analysis of predicted loss-of-function variants in UK Biobank identifies variants protective for disease. Nat. Commun. 9, 1613 (2018).
Satterstrom, F. K. et al. Autism spectrum disorder and attention deficit hyperactivity disorder have a similar burden of rare protein-truncating variants. Nat. Neurosci. 22, 1961–1965 (2019).
de Andrade, K. C. et al. Variable population prevalence estimates of germline TP53 variants: a gnomAD-based analysis. Hum. Mutat. 40, 97–105 (2019).
Laver, T. W. et al. Analysis of large-scale sequencing cohorts does not support the role of variants in UCP2 as a cause of hyperinsulinaemic hypoglycaemia. Hum. Mutat. 38, 1442–1444 (2017).
Sundaram, L. et al. Predicting the clinical impact of human mutation with deep neural networks. Nat. Genet. 50, 1161–1170 (2018).
Glassberg, E. C., Lan, X. & Pritchard, J. K. Evidence for weak selective constraint on human gene expression. Genetics 211, 757–772 (2019).
El-Brolosy, M. A. et al. Genetic compensation triggered by mutant mRNA degradation. Nature 568, 193–197 (2019).
Tuladhar, R. et al. CRISPR-Cas9-based mutagenesis frequently provokes on-target mRNA misregulation. Nat. Commun. 10, 4056 (2019).
Findlay, G. M. et al. Accurate classification of BRCA1 variants with saturation genome editing. Nature 562, 217–222 (2018).
Short, P. J. et al. De novo mutations in regulatory elements in neurodevelopmental disorders. Nature 555, 611–616 (2018).
Martin, A. R., Kanai, M., Kamatani, Y., Neale, B. M. & Daly, M. J. Hidden ‘risk’ in polygenic scores: clinical use today could exacerbate health disparities. Nat. Genet. 51, 584–591 (2019).
Fuller, Z., Berg, J. J., Mostafavi, H., Sella, G. & Przeworski, M. Measuring intolerance to mutation in human genetics. Nat. Genet. 51, 772–776 (2019).
McInnes, L., Healy, J., Saul, N. & Großberger, L. UMAP: Uniform Manifold Approximation and Projection. J. Open Source Softw. 3, 861 (2018).
Diaz-Papkovich, A., Anderson-Trocme, L. & Gravel, S. UMAP reveals cryptic population structure and phenotype heterogeneity in large genomic cohorts. PLoS Genet. (2018). https://doi.org/10.1371/journal.pgen.1008432
Finucane, H. K. Partitioning heritability by functional annotation using genome-wide association summary statistics. Nat. Genet. 47, 1228–1235 (2015).
Zook, J. M. et al. Integrating human sequence data sets provides a resource of benchmark SNP and indel genotype calls. Nat. Biotechnol. 32, 246–251 (2014).
Li, H. et al. A synthetic-diploid benchmark for accurate variant-calling evaluation. Nat. Methods 15, 595–597 (2018).
Fromer, M. et al. De novo mutations in schizophrenia implicate synaptic networks. Nature 506, 179–184 (2014).
Neale, B. M. et al. Patterns and rates of exonic de novo mutations in autism spectrum disorders. Naturey 485, 242–245 (2012).
